AREXVY, powder and suspension for injectable suspension. respiratory syncytial virus vaccine (vrs) (recombinant, with adjuvant) bottle, 0.5 ml
Active ingredients: GLYCOPROTÉINE F RECOMBINANTE DU VIRUS RESPIRATOIRE SYNCYTIAL STABILISÉE EN FORME PRÉ-FUSION
Commercialized according to BDPMDispensing in France: Prescription only
Powder and suspension for injectable suspensionbottle, 0.5 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AREXVY, poudre et suspension pour suspension injectable. Vaccin du Virus Respiratoire Syncytial (VRS) (recombinant, avec adjuvant)
- Pharmaceutical form
- poudre et suspension pour suspension injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon en verre de 120 microgrammes de poudre - 1 flacon en verre de 0,5 ml de suspension
- Marketing authorisation holder
- GLAXOSMITHKLINE BIOLOGICALS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 4 Sept 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64431629CIP73027417CIP133400930274170Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLYCOPROTÉINE F RECOMBINANTE DU VIRUS RESPIRATOIRE SYNCYTIAL STABILISÉE EN FORME PRÉ-FUSIONpoudre | 120 microgrammes · une dose de 0,5 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.